FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.
Expert Rev Mol Diagn. 2009;9(7):709-720. Furthermore, loss-of-function mutations in the p53 protein are found in more than 65% of low-grade astroctytomas, anaplastic astrocytomas and secondary GBM, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results